Loading...

FLNA FILANA THERAPEUTICS INC Product Launches 8-K Filing

FLN

FLN

FILANA THERAPEUTICS INC

(FLNA)

2025 8-K

Financial Update

Board Resignation

Financial Condition Update

Name Change Announcement

Inquiry Closure

Settlement Agreement

Board Appointment Update

FDA Holds Trial

Executive Bonuses Awarded

FDA Requirements Update

Earnings Update

Indictment Dismissed

Board Appointment

Corporate Presentation

Financial Update

Investor Meetings

Earnings Releases

Management Changes

Product Discontinuation

Bonus Plan Update

Financial Results

License Agreement

Workforce Reduction

Study Discontinuation

Financial Results

Open Letter Update

CEO Compensation Details

Consulting Agreement

CEO Appointment

Financial Results and Direc...

Regulation FD Disclosure

Resignation and Appointment

Update on Government Invest...

Management Changes

Annual Meeting of Stockholders

Earnings Reports

Results of Operations and F...

Warrant Distribution

Appointment of Directors

Earnings Reports

Bylaws Amendment

Results of Operations and F...

Annual Meeting of Stockholders

Termination and New Sales A...

Earnings Reports

Management Changes

No Financial Exposure to Banks

Results of Operations and F...

External Links:

On March 25, 2025, Cassava Sciences announced that its Phase 3 study of simufilam for Alzheimer's disease failed to meet key endpoints, leading to the discontinuation of the drug's development.

AI Assistant

FILANA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.